Materias dentro de su búsqueda.
Materias dentro de su búsqueda.
Historia
24
Películas cinematográficas
16
Música popular
13
Novela estadounidense
12
Jazz
10
Música para órgano
7
Crítica e interpretación
6
Música rock
6
Correspondencia
5
Comedy films
4
Condiciones sociales
4
Diarios íntimos
4
Estados Unidos
4
Música
4
Música vocal (Jazz)
4
Novelistas ingleses
4
Arte
3
Aspectos sociales
3
Bailarines
3
Blues (Música)
3
Christmas music
3
Foreign films
3
Historia y crítica
3
Libros falsos
3
Literatura estadounidense
3
Motetes
3
Música de jazz
3
Operas
3
Songs (High voice) with piano
3
Songs (Medium voice) with piano
3
-
3481“…Stromal CD10 showed positive correlation with tumour grade, HER2-neu (P = .000), and ki67 (P = .027), negative correlation with ER and PR. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3482por Martin, Vittoria, Camponovo, Antonella, Ghisletta, Morena, Bongiovanni, Massimo, Mazzucchelli, Luca“…International guidelines for ERBB2 (HER2) testing procedures in breast cancer patients highlight the importance of external quality control. …”
Publicado 2012
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3483
-
3484
-
3485
-
3486“…The objectives of this study were to quantify alterations in protein expression in two HER2+ cellular models of breast cancer and to infer differentially regulated signaling pathways in these models associated with the hallmarks of cancer. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3487por Goud, Kalal Iravathy, Dayakar, Seetha, Vijayalaxmi, Kolanupaka, Babu, Saidam Jangu, Vijay, Anand Reddy P.“…BACKGROUND & OBJECTIVES: Fluorescence in situ hybridization (FISH) is increasingly being recognized as the most accurate and predictive test for HER2/neu gene amplification and response to therapy in breast cancer. …”
Publicado 2012
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3488por Yanagawa, Masumi, Ikemot, Kenzo, Kawauchi, Shigeto, Furuya, Tomoko, Yamamoto, Shigeru, Oka, Masaaki, Oga, Atunori, Nagashima, Yukiko, Sasaki, Kohsuke“…METHODS: Invasive breast cancers (n = 363) were immunohistochemically classified as follows: 111 (30.6%) as luminal A, 95 (26.2%) as luminal B (HER2 negative), 69 (19.0%) as luminal B (HER2 positive), 41 (11.3%) as HER2, and 47 (12.9%) as basal-like subtypes. …”
Publicado 2012
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3489por Jijon, Humberto B., Buret, Andre, Hirota, Christina L., Hollenberg, Morley D., Beck, Paul L.“…TNF-α treatment of IECs resulted in an association between EGFR and HER2 and inhibition of HER2 using a specific inhibitor AG879 in combination with AG1478-suppressed TNF-α-dependent ERK phosphorylation and IL-8 release. …”
Publicado 2012
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3490por Kute, Timothy, Stehle, Jr., John R., Ornelles, David, Walker, Natalie, Delbono, Osvaldo, Vaughn, James P.“…Use of the antibody trastuzumab to kill HER2+ breast cancer cells is an attractive therapy because of its specificity and minimal adverse effects. …”
Publicado 2012
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3491por Teixidó, Cristina, Marés, Rosó, Aracil, Miguel, Ramón y Cajal, Santiago, Hernández-Losa, Javier“…Furthermore, a direct correlation between basal HER3 expression and sensitivity to elisidepsin was observed; moreover, modulation of HER3 expression levels in different cancer cell lines alter their sensitivities to the drug, making them more resistant when HER3 expression is downregulated by a HER3-specific short hairpin RNA and more sensitive when the receptor is overexpressed. …”
Publicado 2013
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3492por BAR-SELA, GIL, HERSHKOVITZ, DOV, HAIM, NISSIM, KAIDAR-PERSON, ORIT, SHULMAN, KATERINA, BEN-IZHAK, OFER“…Human epidermal growth factor 2 (HER2) positivity rates for gastric or gastroesophageal junction (GEJ) adenocarcinoma have been reported at 15–25%. …”
Publicado 2013
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3493por Ben Slima, Ahlem, Ali, Manel Ben, Barkallah, Mohamed, Traore, Al Ibrahim, Boudawara, Tahia, Allouche, Noureddine, Gdoura, RadhouaneEnlace del recurso
Publicado 2013
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3494por Ma, Huiyan, Lu, Yani, Malone, Kathleen E, Marchbanks, Polly A, Deapen, Dennis M, Spirtas, Robert, Burkman, Ronald T, Strom, Brian L, McDonald, Jill A, Folger, Suzanne G, Simon, Michael S, Sullivan-Halley, Jane, Press, Michael F, Bernstein, Leslie“…However, few studies have investigated the black-white disparity in mortality risk stratified by breast cancer subtype, defined by estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status. Furthermore, it is not known whether additional consideration of p53 protein status influences black-white differences in mortality risk observed when considering subtypes defined by ER, PR and HER2 status. …”
Publicado 2013
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3495“…Trastuzumab (Herceptin®), an anti-Her-2 monoclonal antibody, has dramatically altered the prognosis of Her-2 positive breast cancer. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3496por Joensuu, Heikki, Kellokumpu-Lehtinen, Pirkko-Liisa, Huovinen, Riikka, Jukkola-Vuorinen, Arja, Tanner, Minna, Kokko, Riitta, Ahlgren, Johan, Auvinen, Päivi, Saarni, Outi, Helle, Leena, Villman, Kenneth, Nyandoto, Paul, Nilsson, Greger, Leinonen, Mika, Kataja, Vesa, Bono, Petri, Lindman, Henrik“…Little information is available about survival outcomes of patients with HER2-positive early breast cancer treated with adjuvant capecitabine-containing chemotherapy with or without trastuzumab. …”
Publicado 2014
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3497“…Clinically, HER2 proto-oncogene amplification is found in about 25–30% of human breast cancers, where it is correlated to a poor prognosis. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3498por LoRusso, Patricia, Venkatakrishnan, Karthik, Chiorean, E. Gabriela, Noe, Dennis, Wu, Jing-Tao, Sankoh, Serap, Corvez, Maria, Sausville, Edward A.“…Steady-state average unbound CSF concentration (geometric mean 1.54 [range, 0.51–4.27] ng/mL; n = 5) at the RP2D was below the 50 % inhibitory concentration (9.3 ng/mL) for inhibition of tyrosine kinase activity in cells expressing recombinant HER2. Best response was stable disease (12 weeks of nonprogression) in 13 patients. …”
Publicado 2013
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3499por Liu, Y J, Shen, D, Yin, X, Gavine, P, Zhang, T, Su, X, Zhan, P, Xu, Y, Lv, J, Qian, J, Liu, C, Sun, Y, Qian, Z, Zhang, J, Gu, Y, Ni, X“…A significant proportion of HER2-negative patients may potentially benefit from MET- or FGFR2-targeted therapies.…”
Publicado 2014
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3500por Hung, Chao-Ming, Huang, Wei-Chien, Pan, Hsiao-Lin, Chien, Pei-Hsuan, Lin, Chih-Wen, Chen, Lei-Chin, Chien, Yu-Fong, Lin, Ching-Chiao, Leow, Kar-Hee, Chen, Wen-Shu, Chen, Jhen-Yu, Ho, Chien-Yi, Hou, Pao-Sheng, Chen, Yun-Ju“…However, it remains unclear whether and how HBx regulates HER2 expression. In this study, our data showed that HBx expression increased HER2 protein level via enhancing its mRNA stability. …”
Publicado 2014
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto